| Literature DB >> 28602484 |
Nayyer Iqbal1, Kamal Haider1, Vinita Sundaram2, Julia Radosevic3, Thierry Burnouf4, Jerard Seghatchian5, Hadi Goubran6.
Abstract
Oncology services utilize about 15% of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies. CrownEntities:
Keywords: Cancer; Prognosis; Recurrence; Red blood cells; Transfusion
Mesh:
Year: 2017 PMID: 28602484 DOI: 10.1016/j.transci.2017.05.014
Source DB: PubMed Journal: Transfus Apher Sci ISSN: 1473-0502 Impact factor: 1.764